Purpose Chronic hepatitis C is an emerging issue in the management of human immunodeficiency virus (HIV) disease because both diseases have the same route of transmission, leading to a very high prevalence of hepatitis C virus (HCV)-coinfection in the HIV-positive patient population. Lopinavir is extensively metabolized by the hepatic cytochrome P450 3A4, and the pharmacokinetics of this protease inhibitor (PI) could be influenced by liver impairment. However, data currently available on the impact of HCV-coinfection on lopinavir plasma concentrations are both limited and conflicting. Methods This was an observational, open-label study in which adult HIV-infected outpatients on stable antiretroviral treatment that included two nucleoside reverse transcriptase inhibitors (NRTIs) plus lopinavir/ritonavir for at least 4 weeks were asked to participate. The trough plasma concentration (C trough ) of lopinavir and ritonavir was assessed at steady state by a validated high-performance liquid chromatography-tandem mass spectrometry method.
Introduction
Although the introduction of highly active antiretroviral therapy (HAART) has led to a significant increase in the survival of patients with human immunodeficiency virus (HIV) infection and acquired immune-deficiency syndrome (AIDS), an ongoing problem is the emergence of clinical complications associated with comorbidities.
The impact of chronic liver diseases has become of increasing concern in the HIV-positive population. The prevalence of hepatitis C virus (HCV) and HIV (HCV/HIV) coinfection is estimated to be approximately 25-30%, and it may be higher than 50% in some countries (such as Italy and Spain) and more than 90% in some subpopulations (such as intravenous drug addicts) [1] [2] [3] . Moreover, liver toxicity is a common adverse event of antiretroviral agents and is expected to occur more commonly in HIV patients with HCV coinfection.
Lopinavir/ritonavir is a medicine that combines these two drugs, both of which are potent, peptidomimetic HIV protease inhibitors (PIs), and is often included in initial therapeutic regimens. Lopinavir is extensively and rapidly metabolized by the hepatic cytochrome P450 (CYP) 3A4 isoenzyme, and its coadministration with low-dose ritonavir (100 mg daily), a potent inhibitor of CYP3A4, significantly improves its pharmacokinetic properties [4] . In particular, CYP3A4 is the major determinant of lopinavir pharmacokinetics, far more than drug transporters P-glycoprotein or multidrug resistance protein 2 (MRP2), and both intestinal and hepatic CYP3A activity are major contributory factors in the low oral bioavailability of this PI [5] . Elevated and prolonged serum levels of lopinavir support twice-daily dosing, or once-daily dosing in antiretroviral-naïve patients. Liver dysfunction associated with chronic hepatitis C could impact on the absorption of the drug, its first-pass metabolism by the enteric tract and the liver, binding to plasma proteins, and plasma protein concentrations, thereby resulting in an increased exposure to lopinavir and the risk of developing adverse events [6, 7] .
The observed variations in antiretroviral pharmacokinetics which result in a wide range of individual patient drug exposures has led to increasing interest in the clinical use of therapeutic drug monitoring (TDM) as an approach to individualize drug dosing, particularly in subjects with liver or renal dysfunction. An additional rationale for the clinical use of TDM includes potential, numerous pharmacokinetic interactions between antiretroviral agents and other drugs that may influence their plasma levels. TDM of PIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs) is straightforward and reproducible, and benefits with regard to optimal drug concentration for full viral suppression and avoidance of drug toxicity have been demonstrated [8] [9] [10] .
Data on the impact of HCV coinfection on lopinavir plasma levels remain controversial, largely because they are currently based on only a few studies involving a small number of patients and have led to conflicting conclusions. The aim of the study reported here was to evaluate the plasma trough concentration of lopinavir/ritonavir in patients coinfected with HIV and hepatitis C virus (HCV) (without liver cirrhosis) and in a control group of HIV-infected subjects without HCV coinfection.
Methods
This was an observational, open-label study in which HIVinfected outpatients attending the Division of Infectious Diseases of S. Orsola-Malpighi Hospital in Bologna between April 2006 and March 2007 and who were on stable antiretroviral treatment that included two nucleoside reverse transcriptase inhibitors (NRTIs) plus lopinavir/ritonavir for at least 4 weeks were asked to participate. The study was approved by the Ethics Committee of S.Orsola-Malpighi Hospital, and written informed consent was obtained from each patient before enrollment.
On the day of blood sampling for the pharmacokinetics analysis, epidemiological data (sex, age, race, risk factors for HIV infection, and HIV disease stage) and anthropometric measurements [body weight, height, and body mass index (BMI)] were assessed. At the same time, a clinical evaluation was carried out, including CD4+ lymphocyte count, plasma HIV viral load (obtained by a branched-DNA assay; Bayer Diagnostic, Milan, Italy, with a lower limit of 50 copies/mL), liver and renal function tests, and serum concentrations of glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. Exclusion criteria were an age <18 years, a recent history of alcohol or drug abuse, acute hepatitis, chronic hepatitis B (defined by the persistent positivity of hepatitis B surface antigen), liver cirrhosis (defined by clinical, biochemical, and/or histopathological features), recent and uncontrolled opportunistic disease, acute severe diseases, renal dysfunction (serum creatinine >1.2 mg/dL), diabetes mellitus, pregnancy or breast-feeding, adherence levels to HAART treatment <95%, current therapy with NNRTIs or other PIs, current lipidlowering or antidiabetic treatment, and concomitant administration of medications or herbal supplements known to affect lopinavir or ritonavir pharmacokinetics. HCV-coinfection was diagnosed by the persistent positivity of HCV serum antibodies and HCV-RNA. According to this evaluation, the enrolled patients were stratified into two groups: without HCV coinfection (HIV+/HCV−) versus patients with HCV-coinfection (HIV+/HCV+).
Lopinavir/ritonavir therapy was administered by capsules at the standard dose of 400/100 mg twice a day after a standardized continental breakfast and after a moderate fatty meal for lunch. The trough plasma concentration (C trough ) of lopinavir and ritonavir was assessed at steady state (>4 weeks after treatment initiation), with blood samples obtained before the morning dose and 10-14 hours after the previous evening dose. The precise times of the predose sample and of the previous evening intake were recorded to ensure accurately timed blood sampling. Trough levels were considered to be within an acceptable sampling time-frame if they fell within a defined time range for lopinavir every 12 h, namely, within 10-14 h after the last dose. Blood samples were collected in 3.0-mL Vacuette EDTA-containing tubes and centrifuged (600 g, 10 min) to obtain plasma samples within 2 h of collection. The plasma samples were frozen at −20°C and sent on dry ice to the Central Laboratory of the S. OrsolaMalpighi Hospital to determine the C trough of lopinavir. After thawing, HIV was inactivated at 56°C for 30 min, then the plasma samples were extracted and subjected to a validated high-performance liquid chromatography (HPLC)-tandem mass spectrometry method, as described by Dickinson et al. [11] . The internal standard (cimetidine) and acetonitrile (400 μL) were added to aliquots (100 μL) of calibrators, quality controls, and patient ultrafiltrate. After mixing, centrifugation, and the addition of ammonium formate buffer (100 μL; 20 mM), the samples were analyzed by HPLCtandem mass spectrometry (10 μL). Fragmentation of parent molecules into daughter ions occurred by electrospray ionization; ions were separated according to their m/z ratio and quantified by the intensity of their respective daughter ions. The suggested minimum target C trough of lopinavir for inhibiting wild-type virus is within the range of 1,000-10,000 ng/mL and has used previously as a guideline for analyzing such data [9, 10, 12] .
The statistical analysis was performed considering lopinavir and ritonavir C trough separately. Variables with a normal distribution were described as the mean (± standard deviation, SD) and compared by an unpaired t test. Median and interquartile range (IQR) were employed to describe variables that did not follow a normal distribution, and these were compared with the Mann-Whitney non-parametric test. Percentages were compared with the χ 2 test or Fisher's exact test, as appropriate. Lopinavir and ritonavir C trough were described using the geometric mean, and inter-individual variability in drug concentrations was expressed as the coefficient of variation (CV%), which was calculated by dividing the SD by the mean. The lopinavir and ritonavir C trough were compared between HIV/HCV-coinfected and HIV-monoinfected patients using the geometric mean ratio (GMR) and the 95% confidence interval (CI). In order to account for the potential influence of sex, BMI, or albumin concentrations in plasma on drug exposure, multiple regression models including these variables were tested. The minimum sample size to detect a difference of ≥30% in the lopinavir C trough between HIV+/HCV+ and HIV+/HCV− patients was 20 in each group, when accepting an α risk of 0.005 and a β risk of 0.20 [9, 13] .
Results
A total of 65 adult Caucasian HIV-positive patients were enrolled into the study. These patients were stratified into two groups with regard to HCV-coinfection, namely, those monoinfected with HIV (45 patients; HIV+/HCV−) and those coinfected with HIV and HCV (20 patients; HIV+/HCV+). The demographic, anthropometric, clinical, and laboratory characteristics of the 65 enrolled patients are summarized in Table 1 .
Persistently elevated serum levels of transaminases [alanine aminotransferase (ALT)>40 UI/L in at least two blood tests obtained in the last 6 months] were registered in 16 of the 20 (80%) HIV/HCV-coinfected patients and in only four of the 45 (8.8%) HIV-monoinfected patients. Among the HIV/HCV-coinfected patients, nine (45%) had previously received an antiviral therapy for HCV infection (interferon or pegylated interferon and ribavirine) with viral breakthrough or relapse, and all nine were currently positive for serum HCV-RNA. Liver biopsy had previously been performed in ten patients, of whom six showed minimal or slight symptoms of chronic hepatitis (Ishak's score ranging from 1 to 9) and four showed moderate signs of chronic hepatitis (Ishak's score ranging from 10 to 15). All patients were at steady-state for lopinavir/ritonavir treatment at the standard dose of 400/100 mg twice daily, as part of a HAART regimen that included two NRTIs. Antiretroviral agents associated with lopinavir/ritonavir are reported in Table 2 .
There were no statistically significant differences between the two patient groups in terms of demographic, anthropometric, and HIV-related clinical and laboratory characteristics, except for biochemical parameters reflecting the HCV-related hepatic disease. In particular, mean values of serum ALT, aspartate aminotranferase, and gamma-glutamyltransferase were significantly higher in HIV/HCV-coinfected patients than in HIV-monoinfected ones. With regard to serum protein and metabolism parameters, there were no statistically significant differences between the two groups in terms of serum levels of glucose, albumin, total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, while mean insulin concentration was significantly greater in HIV+/HCV+ patients than in HIV+/HCV− ones. The duration of current antiretroviral therapy and total exposure to lopinavir/ritonavir were comparable in both groups, such as the immune-virological parameters. Plasma HIV viral load was undetectable (<50 copies/mL) in 80 and 75% of HIV+/HCV− and HIV+/HCV+ patients, respectively, while the mean (SD) HIV viral load in patients with detectable viremia was 5,500 (3,200) copies/mL and 2,800 (1,900) copies/mL, respectively (p=0.51).
Plasma concentrations showed a great interindividual variability in both groups, but almost all samples were found to be within the therapeutic plasma level range (97% in the HIV+/HCV− group and 100% in the HIV+/HCV+ group). The geometric mean plasma C trough of lopinavir was 5,931 ng/mL (118%) in HIV+/HCV− patients and 6,872 ng/mL (173%) in HIV+/HCV+ ones, as shown in Table 3 . Therefore, the presence of HCV-coinfection was not considered to be significant (GMR 0.89, 95% CI 0.61-1.42; p=0.581). No significant relationship between lopinavir C trough and sex, BMI, or albumin concentration were observed (Table 3) .
Possible correlations between trough plasma concentration of lopinavir and some drug-related adverse events were also investigated. The geometric mean C trough of lopinavir in patients experiencing recent diarrhoea (≥3 evacuations daily with watery feces in the last 2 days) or hypertriglyceridemia (serum triglyceride >250 mg/dL in at least 2 blood tests in the last 6 months) were compared with those of subjects without diarrhea and hypertriglyceridemia. The geometric mean plasma C trough of lopinavir was 6,121 ng/mL (91%) in patients with diarrhoea and 6,787 ng/mL (117%) in those without this symptom; this difference was not statistically significant (GMR 0.94, 95% CI 0.51-1.38; p=0.471). At the same time, the geometric mean plasma C trough of lopinavir was 6,118 ng/mL (79%) in patients with hypertriglyceridemia and 6,915 ng/mL (141%) in those with normal serum Finally, the geometric mean plasma C trough of ritonavir tested 258 ng/mL (81%) in HIV+/HCV− patients and 274 ng/mL (106%) in HIV+/HCV+ ones, a statistically nonsignificant difference (GMR 0.97, 95% CI 0.65-1.38; p=0.712). Similarly, no significant relationship between ritonavir C trough and sex, BMI, or albumin concentration were registered (Table 3) .
Discussion
It is not clear whether enzyme induction or inhibition is likely to be affected in patients with hepatic dysfunction, and the final pharmacokinetic changes in PIs associated with chronic hepatitis are currently still unknown. The effects of liver disease on pharmacokinetics are highly variable because the pathogenetic mechanisms are complex, and they are not well understood. Liver dysfunction may include a wide range of pathophysiologic abnormalities, such as a reduction in blood flow, extrahepatic or interhepatic blood shunting, hepatocyte dysfunction, quantitative and qualitative changes in serum proteins, and changes in biliary flow.
Data on the consequences of chronic hepatitis C on lopinavir serum levels in HIV-infected patients are currently based on only a few studies involving a small number of subjects and have led to conflicting results.
Peng et al. [14] reported the results of an observational, open-label study that assessed the pharamcokinetics of lopinavir/ritonavir in 24 HIV-infected patients receiving a stable antiretroviral treatment for at least 2 weeks prior to and during the study. The patient cohort comprised 12 subjects with mild or moderate liver impairment (associated with chronic hepatitis C or chronic alcoholism) and 12 subjects with normal hepatic function. Chronic liver disease was associated with a significant increase in plasma exposure to lopinavir: the maximum plasma concentration (C max ) and the area under the plasma concentration-time curve from 0 to 12 h (AUC 12 ) were increased by 20-30% compared to the control group. Moreover, liver impairment increased unbound lopinavir AUC 12 by 68% and C max by 56% [14] .
In a study by Barreiro et al. [15] , plasma drug levels of nevirapine, efavirenz, lopinavir/ritonavir, and atazanavir were measured in 268 HIV/HCV-coinfected patients. Overall, drug levels of efavirenz and nevirapine were significantly higher in subjects with hepatic cirrhosis than in those without cirrhosis, while plasma levels of lopinavir and atazanavir did not differ significantly between patients with and without cirrhosis. The authors concluded that hepatic insufficiency was associated with a significant impairment in the liver clearance of NNRTIs, particularly efavirenz, while they observed no similar effects for PIs [15] .
The impact of substance use and hepatitis virus coinfection on plasma PI trough concentrations was evaluated by Slish et al. [16] in 60 HIV-infected patients established on an atazanavir/ritonavir-or lopinavir/ritonavir-containing regimen. Substance use was associated with a marked decrease in lopinavir C trough , and significantly lower lopinavir trough levels were also noted among patients with active chronic hepatitis C evaluated as an independent variable. On the contrary, substance use and HCV-coinfection showed limited effects on atazanavir trough levels. In this cohort, despite the wide interindividual variability of PI trough concentrations, substance use and active chronic hepatitis C were significantly associated with a lower C trough of lopinavir [16] . However, this association was not been found in other studies. Canta et al. [17] carried out an observational, prospective study involving 78 HIV-monoinfected and 71 HIV/HCV-coinfected non-cirrhotic patients in which liver function test results and steady-state lopinavir C trough values were obtained at 1, 3, 6, and 12 months. These researchers observed that the incidence of moderate-to-severe increase in transaminases was significantly higher in HCV-coinfected subjects, but that the pharmacokinetics of lopinavir-ritonavir, as assessed by serial measurements of C trough , were not different in the two groups. They also found no association between the serum concentration of lopinavir and the development of hepatotoxicity [17] .
A cross-sectional, comparative study performed by Moltò et al. [18] assessed lopinavir and ritonavir pharmacokinetics in 26 HIV-monoinfected patients and 22 HIV/HCV-coinfected subjects; moreover, HCV-positive subjects were grouped according to the presence/absence of an underlying advanced hepatic fibrosis, respectively. Lopinavir and ritonavir pharmacokinetics were comparable between HCV-negative and HCV-positive patients without liver function impairment, but PI plasma levels show significant differences in the HCVpositive group with advanced liver disease. The apparent volume of distribution after oral administration of lopinavir was 125% higher in HCV-positive subjects with advanced liver fibrosis than in HCV-negative individuals, and 107% higher than that in HCV-positive subjects without advanced fibrosis. For ritonavir, the AUC 12 and maximum and minimum plasma concentrations in HCV-positive patients with advanced fibrosis were 63, 86, and 100% higher, respectively, than these parameters in the HCV-negative controls [18] .
In a prospective, open-label study, Micheli et al. [19] evaluated the pharmacokinetics of total and unbound lopinavir in 56 HIV-infected patients (24 HIV-monoinfected, 23 HIV/HCV-coinfected, and 9 HIV/HCV-coinfected with liver cirrhosis). No significant differences in AUC 12 , C trough , or apparent oral clearance of total and unbound lopinavir were observed among the three groups. However, chronic liver impairment produced a slight, although not significant, decrease in plasma protein binding, and the free-fraction of lopinavir increased from 0.97% in HIV-monoinfected patients to 1.18% in HIV/HCV-coinfected patients with liver cirrhosis. No significant changes in the pharmacokinetics of total and unbound lopinavir were showed in patients with liver dysfunction and morphologic evidence of cirrhosis, possibly because of the potent inhibitory effect of ritonavir on lopinavir metabolism [19] .
In our study, mean plasma trough concentrations of lopinavir and ritonavir were comparable in HIV-monoinfected and HIV/HCV-coinfected patients without liver cirrhosis, and the pharmacokinetics of these PIs was not significantly influenced by the presence of HCV coinfection, even though plasma drug concentrations showed a great inter-individual variability in both groups. Similarly, no statistically significant correlations were found between mean C trough of lopinavir and commonly encountered adverse effects (such as diarrhoea and hypertriglyceridaemia), immune-virological parameters of HIV disease, different kind of nucleoside analogs, presence of lipodystrophy, plasma concentrations of total cholesterol, LDL cholesterol, and glucose. Despite a large variation in antiretroviral drug plasma levels, single-measurement TDM may be sufficient in the routine management of such patients to assess if the PI C trough is within the therapeutic plasma level range, as shown by Donnerer et al. [20] .
Chronic liver disease is usually associated with chronic hepatocyte damage and decreased cell function, with a 50% reduction in cytochrome P450 content. In general, chronic hepatic dysfunction and changes in hepatocellular mass may produce a reduction in the intrinsic clearance of several drugs, leading to a marked increase in their plasma levels and risk of potential toxicity. The absence of significant changes in lopinavir plasma concentrations among HIV-infected patients with chronic hepatitis C could be explained by the distinguishing pharmacokinetics of coformulated lopinavir/ritonavir. Because ritonavir usually inhibits the liver metabolism of lopinavir and thus decreases lopinavir hepatic clearance, the reduction in lopinavir intrinsic clearance in subjects with hepatic impairment may be absent or less pronounced.
These pharmacokinetic data suggest that no adjustment of lopinavir/ritonavir dosing is requested in HIV/HCV-coinfected patients without liver cirrhosis, even though caution is always necessary for the administration of PIs in subjects with chronic liver diseases and, notably, in those with hepatic cirrhosis. Further, enlarged studies are certainly required to better investigate the pharmacokinetic changes in PIs in HIVinfected patients with HCV-coinfection.
